Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Photo

US FDA Grants Orphan Drug Status to FibroGen's FG-3019 to Treat Idiopathic Pulmonary Fibrosis.

FibroGen FG-3019 pulmonary fibrosis drug orphan drug monoclonal antibody

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,616 posts
  • Location:West Sussex

Posted 16 May 2013 - 10:19 PM

US FDA Grants Orphan Drug Status to FibroGen's FG-3019 to Treat Idiopathic Pulmonary Fibrosis.

 

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to FibroGen's FG-3019, the human monoclonal antibody against connective tissue growth factor (CTGF), for the treatment of idiopathic pulmonary fibrosis (IPF). CheckOrphan. 08/02/12. (Also see: Pulmonary Fibrosis Treatments)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

 


Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)